A Phase 2 interventional study of Iressa (Gefitinib) and Irinotecan in Metastatic Colorectal Cancer, sponsored by AstraZeneca. Withdrawn at 13 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-27.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 200 studies testing irinotecan in Colorectal Neoplasms — 25 open to participants now, 32 under way, 6 of them phase 3. Irinotecan · Colorectal Neoplasms.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, this one is the 26th largest by enrollment of the 182 interventional ones that give a count, is one of 9 that started in 2004, is one of 117 in phase 2, and was the 55th registered.
6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →25 of the 200 studies testing irinotecan in Colorectal Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18+
Gruppo Oncologico Italia Meridionale · Sites in Italy
Ages 18+
Sun Yat-sen University · Sites in China
Ages 18–80
Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Sites in China
Ages 18–70
Shanghai Zhongshan Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
Irinotecan: first FDA approval 1996 (CAMPTOSAR), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
200 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 48 · Phase 2 139 · Phase 3 28 · Phase 4 2
First in 1996; this study’s year is marked. 9 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 190 is above the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 47 across the 182 interventional studies. Of the 131 that completed or were terminated, 27 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 200 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
29 studies in Colorectal Neoplasms by AstraZeneca: 2 open now, 8 under way, none of them phase 3. Of 19 finished, 7 (37%) have results posted.
Among the 29 studies in Colorectal Neoplasms by AstraZeneca, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2004, is one of 12 in phase 2, and was the 2nd registered.
AstraZeneca’s Colorectal Neoplasms studies by the year they started, since 2003.
7 of the studies testing irinotecan in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03303495Phase 3Sun Yat-sen UniversityA Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC | 2026-12-31 |
| NCT06321081Beijing HospitalICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC | 2026-12-30 |
| NCT07229846Yanqiao ZhangA Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation | 2027-02 |
| NCT05391126Reema A. PatelGENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care | 2027-05 |
| NCT07570914Tianjin Medical University Cancer Institute and HospitalHepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases | 2027-05-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 200 studies testing irinotecan in Colorectal Neoplasms, from their registry updates:
Among AstraZeneca’s 29 in Colorectal Neoplasms:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan, 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening (Time to Progression) in patients with metastatic colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Time to progression (6 months after Last patient in)
Objective Response Rate, Duration of Response, Disease control rate, Overall Survival, (6 months after Last patient in)
The record gives a start of Jul 2004, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gefitinib · Irinotecan · Fluorouracil · Leucovorin